Guidelines to document H. pylori antimicrobial resistance in the North America: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}; {{AE}} {{MKK}}, {{SSW}} | {{CMG}}; {{AE}} {{MKK}}, {{SSW}} | ||
==2017 ACG Guidelines to document H. pylori antimicrobial resistance in the North America== | ==2017 ACG Guidelines to document H. pylori antimicrobial resistance in the North America== | ||
Line 7: | Line 8: | ||
| colspan="1" style="text-align:center; background:LightGreen" |Strong recommendation | | colspan="1" style="text-align:center; background:LightGreen" |Strong recommendation | ||
|- | |- | ||
| bgcolor="LightGreen" |1. | | bgcolor="LightGreen" |1.Data regarding antibiotic resistance among H. pylori strains from North America remains scarce. Organized efforts are needed to document local, regional, | ||
and national patterns of resistance in order to guide the appropriate selection of H. pylori therapy | |||
|- | |- | ||
|} | |} |
Revision as of 19:39, 1 December 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2], Sargun Singh Walia M.B.B.S.[3]
2017 ACG Guidelines to document H. pylori antimicrobial resistance in the North America
Strong recommendation |
1.Data regarding antibiotic resistance among H. pylori strains from North America remains scarce. Organized efforts are needed to document local, regional,
and national patterns of resistance in order to guide the appropriate selection of H. pylori therapy |